@article {Cherem2021.09.29.21264314, author = {Jos{\'e} Cherem and Victor Satler Pylro and Katia Poles and Richardson Costa Carvalho and Ewerton Carvalho and Juliana Anacleto dos Santos and Ingrid Marciano Alvarenga and Denise Alvarenga Rocha and Karla Silva Teixeira and Joseane Camilla de Castro and Mariana Almeida Torquete and Sidney de Almeida Ferreira and Joziana Muniz de Paiva Bar{\c c}ante}, title = {Telemedicine and molecular Sars-CoV-2 early detection to face the COVID-19 pandemic}, elocation-id = {2021.09.29.21264314}, year = {2021}, doi = {10.1101/2021.09.29.21264314}, publisher = {Cold Spring Harbor Laboratory Press}, abstract = {The COVID-19 pandemic brought a series of challenges to the academic community. Social distancing measures imposed the interruption of face-to-face activities besides the implementation of remote work and online classes. For safe and gradual return, the monitoring of individuals, quick detection of infection, contact tracing, and isolation of those infected became essential. In this sense, we developed strategies to face the pandemic at the Federal University of Lavras (UFLA) - Brazil. A Telemedicine Program (TeleCovid) and the assemblage of a laboratory for SARS-CoV-2 molecular diagnosis (LabCovid) were essential measures for monitoring, preventing, and controlling outbreaks at the university. TeleCovid works with a team of students who guide and answer questions regarding COVID-19 and, when necessary, make the referral for online consultation with medical professionals. In the suspicion of SARS-CoV-2 infection, the doctor refers the patient for testing at LabCovid. LabCovid performs the sample collection using nasal swabs, followed by processing samples by the RT-qPCR method. We have placed all positive patients in isolation and tested their contacts. This approach meant that positive cases were identified early, thus avoiding outbreaks in different environments in face-to-face activities.Competing Interest StatementThe authors have declared no competing interest.Funding StatementWe declare no competing interests. We thank all the technicians of the LabCovid, UFLA for processing the samples. This work was supported by the Ministry of Education Brazil (grant number: TED 9227); UFLA 044/2020; PML 017/2020 and by the Brazilian Microbiome Project. Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Ethical Committee of Federal University of Lavras. CAAE number: 43997221.6.0000.5148All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data referred to in the manuscript are available.}, URL = {https://www.medrxiv.org/content/early/2021/10/02/2021.09.29.21264314}, eprint = {https://www.medrxiv.org/content/early/2021/10/02/2021.09.29.21264314.full.pdf}, journal = {medRxiv} }